Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: BAT2206
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: $150.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement August 27, 2021
Under the agreement, Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206. Hikma will have exclusive rights to commercialize the product in the US.